Literature DB >> 22294766

The role of ABC transporters in progression and clinical outcome of colorectal cancer.

I Hlavata1, B Mohelnikova-Duchonova, R Vaclavikova, V Liska, P Pitule, P Novak, J Bruha, O Vycital, L Holubec, V Treska, P Vodicka, P Soucek.   

Abstract

Worldwide, colorectal cancer (CRC) is the third most common cancer, with the highest mortality rates occurring in Central Europe. The use of chemotherapy to treat CRC is limited by the inter-individual variability in drug response and the development of cancer cell resistance. ATP-binding cassette (ABC) transporters play a crucial role in the development of resistance by the efflux of anticancer agents outside of cancer cells. The aim of this study was to explore transcript levels of all human ABCs in tumours and non-neoplastic control tissues from CRC patients collected before the first line of treatment by 5-fluorouracil (5-FU)-containing regimen. The prognostic potential of ABCs was evaluated by the correlation of transcript levels with clinical factors. Relations between transcript levels of ABCs in tumours and chemotherapy efficacy were also addressed. The transcript profile of all known human ABCs was assessed using real-time polymerase chain reaction with a relative standard curve. The majority of the studied ABCs were down-regulated or unchanged between tumours and control tissues. ABCA12, ABCA13, ABCB6, ABCC1, ABCC2 and ABCE1 were up-regulated in tumours versus control tissues. Transcript levels of ABCA12, ABCC7 and ABCC8 increased in direction from colon to rectum. Additionally, transcript levels of ABCB9, ABCB11, ABCG5 and ABCG8 followed the reverse significant trend, i.e. a decrease in direction from colon to rectum. The transcript level of ABCC10 in tumours correlated with the grade (P = 0.01). Transcript levels of ABCC6, ABCC11, ABCF1 and ABCF2 were significantly lower in non-responders to palliative chemotherapy in comparison with responders. The disease-free interval of patients treated by adjuvant chemotherapy was significantly shorter in patients with low transcript levels of ABCA7, ABCA13, ABCB4, ABCC11 and ABCD4. In conclusion, ABCC11 may be a promising candidate marker for a validation study on 5-FU therapy outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22294766     DOI: 10.1093/mutage/ger075

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  82 in total

1.  Identification and Quantification of Drug-Resistant Cells in Colorectal Tumor and Distal Margin.

Authors:  K Chandramohan; Tapas Pradhan; S Asha Nair
Journal:  Indian J Surg Oncol       Date:  2017-02-11

Review 2.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

3.  A weighted exact test for mutually exclusive mutations in cancer.

Authors:  Mark D M Leiserson; Matthew A Reyna; Benjamin J Raphael
Journal:  Bioinformatics       Date:  2016-09-01       Impact factor: 6.937

4.  Reviewing the role of P2Y receptors in specific gastrointestinal cancers.

Authors:  Steve Dagenais Bellefeuille; Caroline M Molle; Fernand-Pierre Gendron
Journal:  Purinergic Signal       Date:  2019-09-02       Impact factor: 3.765

5.  DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.

Authors:  Elisabetta Bigagli; Carlotta De Filippo; Cinzia Castagnini; Simona Toti; Francesco Acquadro; Francesco Giudici; Marilena Fazi; Piero Dolara; Luca Messerini; Francesco Tonelli; Cristina Luceri
Journal:  Cell Oncol (Dordr)       Date:  2016-10-05       Impact factor: 6.730

6.  Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Authors:  Ning Ji; Yuqi Yang; Chao-Yun Cai; Zi-Ning Lei; Jing-Quan Wang; Pranav Gupta; Suneet Shukla; Suresh V Ambudkar; Dexin Kong; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-10       Impact factor: 8.679

7.  SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma.

Authors:  Viktor Hlavac; Radka Vaclavikova; Veronika Brynychova; Pavel Dvorak; Katerina Elsnerova; Renata Kozevnikovova; Karel Raus; Katerina Kopeckova; Sona Mestakova; David Vrana; Jiri Gatek; Pavel Soucek
Journal:  Mol Diagn Ther       Date:  2021-01-02       Impact factor: 4.074

8.  ABCE1 is essential for S phase progression in human cells.

Authors:  Marina Toompuu; Kairi Kärblane; Pille Pata; Erkki Truve; Cecilia Sarmiento
Journal:  Cell Cycle       Date:  2016-03-17       Impact factor: 4.534

9.  ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Authors:  Antonin Dréan; Shai Rosenberg; François-Xavier Lejeune; Larissa Goli; Aravindan Arun Nadaradjane; Jérémy Guehennec; Charlotte Schmitt; Maïté Verreault; Franck Bielle; Karima Mokhtari; Marc Sanson; Alexandre Carpentier; Jean-Yves Delattre; Ahmed Idbaih
Journal:  J Neurooncol       Date:  2018-03-08       Impact factor: 4.130

10.  Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies.

Authors:  Hemantkumar Chavan; Mohiuddin Md Taimur Khan; George Tegos; Partha Krishnamurthy
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.